Company ne kaha hai ki usne apni nai dawai ke liye final approval prapt kar liya hai.. US Food and Drug Administration (USFDA) ne Zituvimet XR (sitagliptin aur metformin hydrochloride) extended-release tablets ko market karne ki ijazat de di hai..
Iske saath, Zydus ke paas Sitagliptin (base) aur combination franchise ke saare teen NDA approvals hain, company ne kaha.
“Zaroori baat yeh hai ki teenon NDA ne first-cycle approval (FCA) haasil kiya,” company ne stated kiya.
Zituvimet XR (sitagliptin aur metformin hydrochloride) extended-release tablets ko diet aur exercise ke saath type 2 diabetes mellitus wale adults ke glycemic control ko improve karne ke liye use kiya jata hai.
Yeh product group ke formulation manufacturing facility, jo Ahmedabad SEZ mein hai, wahan manufacture kiya jayega, Zydus Lifesciences ne kaha.
IQVIA (MAT May 2024) ke mutabik, US market mein DPP-IV inhibitors (oral diabetes medications) aur inke combinations ki value USD 9.5 billion thi.
Zydus Lifesciences ke shares BSE par 2.04 percent gir kar Rs 1,161.10 per share ke level par trade kar rahe the.
Disclaimer- This article is for educational purposes only. Do not invest your hard-earned money without consulting your financial advisor and conducting your analysis.
